US EditionEuropean Commission Approves HIV Prevention Injection - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
News on the Day and the Hour Latest News Today The European Commission (EC) recently authorized the marketing of the drug lenacapavir, a six-monthly injectable medicine designed to prevent HIV infection in adults and adolescents at higher risk. According to information from the Gilead laboratory, the medicine will be released under the name of Yeytuo, given in two doses a year, and will be available in all 27 countries of the European Union, as…
An injection of Lenacapavir prevents contagion for six months
Brussels has authorized the marketing of the drug from the pharmaceutical company Gilead, which is 99.9% effective in preventing the virus for six months
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium